Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Clinical and experimental studies suggest that bosentan could delay the progression of interstitial lung disease (ILD) associated with systemic sclerosis (SSc), a condition for which no established efficacious treatment is available. The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO Class III and IV, to a new category of patients suffering from ILD associated with SSc.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Main inclusion criteria:
- Systemic Sclerosis diffuse or limited
- Significant Interstitial Lung Disease on HRCTscan
- DLco < 80% predicted
- Dyspnea on exertion
- Walk not limited by musculoskeletal reasons
Main exclusion criteria:
- Interstitial Lung Disease due to other conditions than SSc
- End stage restrictive or obstructive lung disease
- Severe cardiac or renal diseases
- Significant pulmonary arterial hypertension
- Smoker (> 5cig./day)
- Treatment with immunosuppressive, antifibrotic drugs, high dose corticosteroids (within 4 weeks of randomization)
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal